Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

(2018) Elisabetta Patorno et al.   BMJ-British Medical Journal

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

(2018) Elisabetta Patorno et al.   BMJ-British Medical Journal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor

(2017) Jacob A. Udell et al.   CIRCULATION

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method

(2014) Joanna IntHout et al.   BMC Medical Research Methodology

Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model

(2013) Marc A. Suchard et al.   ACM Transactions on Modeling and Computer Simulation

High-dimensional, massive sample-size Cox proportional hazards regression for survival analysis

(2013) S. Mittal et al.   BIOSTATISTICS

Defining a Reference Set to Support Methodological Research in Drug Safety

(2013) Patrick B. Ryan et al.   DRUG SAFETY

Interpreting observational studies: why empirical calibration is needed to correctp-values

(2013) Martijn J. Schuemie et al.   STATISTICS IN MEDICINE